Evidence map›Paper›PMID 36744262›Full record

ArticleFrontiers in pharmacology2023

Feiyiliu Mixture sensitizes EGFR

Jingjing Shi, Shaoyu Hao, Xiantao Liu, Yingying Li, Xin Zheng

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Jingjing ShiCollege of First Clinical Medical, Shandong University of Traditional Chinese Medicine, Jinan, China.
Shaoyu HaoDepartment of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xiantao LiuDepartment of Respiratory Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Yingying LiCollege of First Clinical Medical, Shandong University of Traditional Chinese Medicine, Jinan, China.
Xin ZhengQingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), Qingdao, China.
Qingdao University · CNAffiliated Hospital of Shandong University of Traditional Chinese Medicine · CNShandong Tumor Hospital · CNShandong University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acquired resistanceFeiyiliu Mixturenon-small cell lung cancerosimertinibPRC1/Wnt/EGFR pathway

Identifiers

PMID36744262
PMCPMC9892466
OpenAlexW4317388031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.